Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies.

Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK.

Physiol Rev. 2008 Jul;88(3):887-918. doi: 10.1152/physrev.00033.2007. Review.

2.

Phenotypic heterogeneity of Marfan-like connective tissue disorders associated with mutations in the transforming growth factor-beta receptor genes.

Akutsu K, Morisaki H, Takeshita S, Sakamoto S, Tamori Y, Yoshimuta T, Yokoyama N, Nonogi H, Ogino H, Morisaki T.

Circ J. 2007 Aug;71(8):1305-9.

3.

LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome.

Boucher P, Li WP, Matz RL, Takayama Y, Auwerx J, Anderson RG, Herz J.

PLoS One. 2007 May 16;2(5):e448.

4.

Marfan syndrome: from molecular pathogenesis to clinical treatment.

Ramirez F, Dietz HC.

Curr Opin Genet Dev. 2007 Jun;17(3):252-8. Epub 2007 Apr 27. Review. Erratum in: Curr Opin Genet Dev. 2007 Aug;17(4):367.

PMID:
17467262
6.

TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome.

Singh KK, Rommel K, Mishra A, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M.

Hum Mutat. 2006 Aug;27(8):770-7.

PMID:
16799921
7.

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC.

Science. 2006 Apr 7;312(5770):117-21.

8.

The molecular genetics of Marfan syndrome and related disorders.

Robinson PN, Arteaga-Solis E, Baldock C, Collod-BĂ©roud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M.

J Med Genet. 2006 Oct;43(10):769-87. Epub 2006 Mar 29. Review.

9.

Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.

Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC.

Mol Cell Biol. 2005 Apr;25(7):2593-606.

10.

TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome.

Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC.

J Clin Invest. 2004 Dec;114(11):1586-92.

11.

PDGF signaling in cells and mice.

Tallquist M, Kazlauskas A.

Cytokine Growth Factor Rev. 2004 Aug;15(4):205-13. Review.

PMID:
15207812
12.

LRP-1/TbetaR-V mediates TGF-beta1-induced growth inhibition in CHO cells.

Tseng WF, Huang SS, Huang JS.

FEBS Lett. 2004 Mar 26;562(1-3):71-8.

13.

Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1.

Huang SS, Ling TY, Tseng WF, Huang YH, Tang FM, Leal SM, Huang JS.

FASEB J. 2003 Nov;17(14):2068-81.

PMID:
14597676
14.
15.
16.

LRP: role in vascular wall integrity and protection from atherosclerosis.

Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J.

Science. 2003 Apr 11;300(5617):329-32.

17.

Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome.

Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC.

Nat Genet. 2003 Mar;33(3):407-11. Epub 2003 Feb 24.

PMID:
12598898
18.

The phosphoinositide 3-kinase pathway.

Cantley LC.

Science. 2002 May 31;296(5573):1655-7. Review.

PMID:
12040186
19.

New responsibilities for the PI3K regulatory subunit p85 alpha.

Okkenhaug K, Vanhaesebroeck B.

Sci STKE. 2001 Jan 16;2001(65):pe1. Review.

PMID:
11752634
20.

Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration.

Swertfeger DK, Bu G, Hui DY.

J Biol Chem. 2002 Feb 8;277(6):4141-6. Epub 2001 Dec 5.

Supplemental Content

Support Center